A meta-analysis was undertaken to examine the relationship between plasma brain natriuretic peptide (BNP) levels and recurrence of atrial fibrillation (AF) after successful electrical cardioversion. The literature search was conducted using key inclusion criteria for papers published between January 1980 and March 2011 listed in the PubMed ® /MEDLINE ® database. Data were analysed using RevMan version 5.1 software; a manual search was also performed. Ten studies were finally included. Results showed that baseline BNP levels were higher in patients with AF recurrence than in those without recurrence, the standardized mean difference in plasma BNP level being −1.35 (95% confidence interval −2.17, −0.53, Z-score for overall effect 3.22). These results suggest that higher plasma BNP levels are associated with a greater risk of AF recurrence. BNP levels may predict AF recurrence after successful electrical cardioversion.
Introduction
Atrial fibrillation (AF) is the most common arrhythmia, especially in the elderly. 1 There are two treatment modalities for AF: rate control and rhythm control. 2 Rhythm control offers several potential benefits, such as prevention of electrical and structural remodelling of the atria, amelioration of symptoms, a decrease in the rate of adverse cardiovascular events and improvement in quality of life. 3 Cardioversion is frequently used to restore sinus rhythm (SR) in patients with AF, but early relapse is common, with a 50 -60% rate of AF recurrence within the first month after treatment. 4 Age, a history of AF, left atrial dilatation, left ventricular dysfunction, defects in left atrial appendage functions and hyperthyroidism have been associated with elevated AF recurrence rates. 5, 6 The plasma concentration of brain natriuretic peptide (BNP) -an index used in the evaluation of relapse of AF -has also been implicated in AF. 7 Brain natriuretic peptide is synthesized a Y Tang and H Yang contributed equally to this article.
Y Tang, H Yang, J Qiu BNP levels and AF recurrence: a meta-analysis mainly by the cardiac ventricles and, to a lesser extent, by the atria. Inoue et al. 8 indicated that plasma levels of BNP are increased in patients with AF. Some observational studies 9 -15 have reported a relationship between BNP and AF recurrence after successful electrical cardioversion, but others have failed to find a relationship. 16 -18 It was, therefore, considered appropriate to undertake a meta-analysis to explore the relationships between BNP and the recurrence of AF after electrical cardioversion.
Materials and methods

LITERATURE SEARCH
The PubMed ® /MEDLINE ® databases were carefully searched to identify relevant publications indexed between January 1980 and March 2011, using the key words 'brain natriuretic peptide', 'cardioversion' and 'atrial fibrillation'. A manual search was also conducted for relevant review articles and for abstracts of the scientific sessions of the American College of Cardiology, the American Heart Association and the European Society of Cardiology for the past 5 years.
INCLUSION CRITERIA
Studies were considered eligible for inclusion in the meta-analysis if they met the following criteria: (i) they were observational studies; (ii) they evaluated the potential relationship between plasma BNP levels before cardioversion and AF recurrence after successful electrical cardioversion; (iii) AF recurrence rates were used as an index of the outcome; and (iv) the follow-up period was ≥ 2 weeks.
ASSESSMENT OF STUDY QUALITY
To examine biases in the studies and their effects, quality assessments were carried out according to the following criteria: (i) whether the inclusion criteria and the end of the event were clearly defined; (ii) whether the follow-up period was adequate; (iii) whether all cases were followed up, i.e. the withdrawal rate was < 20%; (iv) whether confounding and predicting factors were distinguished; and (v) whether there was a clear description of the detection system used to identify the incident endpoint. 
DATA EXTRACTION
STATISTICAL ANALYSES
Data were collected and analysed using RevMan version 5.1 software (Cochrane IMS, Oxford, UK). Data heterogeneity was analysed using the χ 2 test (α = 0.1), with the extent of heterogeneity determined using the I 2 method. 20 A value of I 2 > 56% was taken to indicate a high level of heterogeneity among studies. Statistical heterogeneity was assessed by merge analysis using a fixed effects model. A random effects model was used to interpret heterogeneity further and improve test performance, and funnel plot analysis was used to investigate possible publication bias. 17
Results
LITERATURE SEARCH
The initial review identified 216 documents Y Tang, H Yang, J Qiu BNP levels and AF recurrence: a meta-analysis of which 10 were selected for analysis.
9 -18 A total of 618 patients were enrolled in these studies: 300 cases were classified in the AF recurrence group and 318 in the SRmaintaining group. Basic characteristics of the 10 studies are shown in Table 1 .
META-ANALYSIS
Findings from the meta-analysis relating to the relationship between plasma BNP level and AF recurrence after successful electrical cardioversion in patients with AF are shown in Fig. 1 . The BNP concentrations in the AF recurrence group were higher than those in the SR-maintaining group, and the difference was statistically significant (P < 0.00001; I 2 = 94%). The differences were related mainly to differences in study subjects, follow-up time, test indicators and outcome measurements. When the random effects model was used to modify partial heterogeneity and improve test performance, the standardized mean difference (SMD) in plasma BNP level was −1.35 (95% CI −2.17, −0.53). Hypothesis testing for overall effect led to a Z-score of 3.22 (P = 0.001). When studies that provided only the median and quartiles rather than mean and SD 14 -16 were discarded and a further metaanalysis was undertaken, the SMD in plasma BNP level was −1.02 (95% CI −1.81, −0.22). The overall effect of hypothesis testing resulted in a Z-score of 2.5 (P = 0.01). A metaanalysis performed after removing the study with the shortest duration of follow-up 11 gave an SMD of −1.38 (95% CI −2.26, −0.50). The Z-score for the overall effect was 3.08 (P = 0.002), indicating that BNP concentrations in the AF recurrence group were significantly higher than those in the SR-maintaining group.
These results following the exclusion of four studies 11,14 -16 from the meta-analysis suggest that the data were statistically heterogeneous. This could be because of differences between patients with AF across the studies (such as the presence or absence of the main heart diseases, e.g. coronary heart disease, hypertensive heart disease and cardiomyopathy), different degrees of severity of heart disease or cardiac function, different durations of follow-up, different BNP levels and the use of different methods to detect the N-terminal of the prostorage form of BNP (NT-proBNP). Analysis of heterogeneity using the random effects model and distribution of data points on a funnel plot indicated that biases were possibly related to language bias and publication bias (Fig. 2) .
Discussion
Meta-analyses are applied to multiple sets of independent research results in order to provide systematic analyses and a comprehensive quantitative synthesis of the data. The characteristics of good metaanalyses include enhanced statistical power, evaluation of inconsistencies between research results, quantitative and comprehensive evaluation of effect sizes and the identification of shortcomings of previous studies. Although meta-analysis is a scientific and rational approach, its usefulness is affected by many factors, such as the number of publications selected for analysis, the total sample size, publication bias and defects of the analytical methods themselves. 21 Brain natriuretic peptide is a cyclic hormone produced in the atria and ventricles of the heart. When secreted, the prostorage form of BNP (proBNP) is decomposed into N-and C-terminal fragments. The N-terminal fragment is the biologically inactive NT-proBNP, whereas the C-terminal fragment is the 32 amino acid, biologically active BNP. 1 BNP entering the Y Tang, H Yang, J Qiu BNP levels and AF recurrence: a meta-analysis Y Tang, H Yang, J Qiu BNP levels and AF recurrence: a meta-analysis blood circulation has strong inhibitory effects on the natriuretic, diuretic, vasodilator and renin-angiotensinaldosterone systems, and inhibits the proliferation of vascular smooth muscle cells and endothelial cells. Ogawa et al. 22 found FIGURE 1: Meta-analysis of the 10 selected published studies on the relationship between brain natriuretic peptide (BNP) concentrations (pg/ml) and the recurrence of atrial fibrillation (AF) after successful electrical cardioversion (SR, sinus rhythm; SMD, standardized mean difference in AF recurrence; IV, inverse variance; CI, confidence interval) that BNP was secreted by ventricular myocytes as a result of ventricular pressure and volume overload or ventricular expansion. Consequently, BNP has become an important indicator in the clinical diagnosis, treatment and prognosis of heart failure. However, there is evidence that BNP is secreted by the atrium in patients in whom AF has occurred. 8 Tuinenburg et al. 23 studied atrial BNP gene expression in patients with paroxysmal and persistent AF, and found that the atrium was the major site of BNP gene expression. Silvet et al. 24 found that that the increase in BNP levels after atrial stretching and volume overload was closely related to chronic AF. In addition, pathological changes such as the enlargement, fibrosis and lipid degeneration of the atrium may also cause an increase in BNP. 25 The question of whether BNP can be used as an effective indicator in the proactive prevention of AF or its recurrence, or in the likelihood of success of cardioversion treatment has, therefore, attracted wide attention.
The present meta-analysis of 10 AFrelated publications 9 -18 showed that, after successful electrical cardioversion, AF was more likely to recur in patients with high, rather than low, plasma BNP concentrations. This indicates that plasma BNP level is a predictor of AF recurrence. When studies providing only medians and quartiles (rather than means and SDs) 14 -16 and the study with the shortest duration of followup 11 were discarded, the sensitivity analysis produced results similar to those obtained when these studies were included. This suggest that the research results were statistically heterogeneous, possibly because of differences in patient characteristics, follow-up duration and analytical methods. Distribution of data points on the funnel plot graph after application of the random effects model indicated possible language and publication biases. As a biochemical indicator, plasma BNP level has the advantages of costeffectiveness, convenience and a high degree of reliability. 26 The measurement of plasma BNP levels could help to predict the risk of recurrence of AF, thus helping the initial selection of suitable patients for AF treatment.
